

RESEARCH ARTICLE

Open Access

Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis

Guillaume Romain¹, Sarah Tremblay¹, Ellen T Arena^{2,5}, L Caetano M Antunes^{2,6}, Scott Covey³, Michael T Chow^{4,7}, B Brett Finlay^{2,3} and Alfredo Menendez^{1*}

Abstract

Background: Enterohepatic bacterial infections have the potential to affect multiple physiological processes of the body. Fibroblast growth factor 15/19 (FGF15 in mice, FGF19 in humans) is a hormone that functions as a central regulator of glucose, lipid and bile acid metabolism. FGF15/19 is produced in the intestine and exert its actions on the liver by signaling through the FGFR4- β Klotho receptor complex. Here, we examined the *in vivo* effects of enterohepatic bacterial infection over the FGF15 endocrine axis.

Results: Infection triggered significant reductions in the intestinal expression of *Fgf15* and its hepatic receptor components (*Fgfr4* and *Klb* (β Klotho)). Infection also resulted in alterations of the expression pattern of genes involved in hepatobiliary function, marked reduction in gallbladder bile volumes and accumulation of hepatic cholesterol and triglycerides. The decrease in ileal *Fgf15* expression was associated with liver bacterial colonization and hepatobiliary pathophysiology rather than with direct intestinal bacterial pathogenesis.

Conclusions: Bacterial pathogens of the enterohepatic system can disturb the homeostasis of the FGF15/19-FGFR4 endocrine axis. These results open up a possible link between FGF15/19-FGFR4 disruptions and the metabolic and nutritional disorders observed in infectious diseases.

Keywords: Endocrine, Metabolism, Enterohepatic, Infection, FGF15, FGF19, FGFR4, β Klotho, *Salmonella*, *Listeria*

Background

Alteration of the host's metabolism is common in infectious diseases; it can lead to patient malnutrition and the need for nutritional support [1,2]. Infection-driven metabolic changes are characterized by an accelerated flux of glucose, lipids, proteins and amino acids that may result in net protein loss and diabetic-like hyperglycemia [1,2]. Significant metabolic disorders have been observed in natural and experimental infections with the bacterium *Salmonella enterica*, including changes of the lipid and protein profiles and widespread hormonal imbalances [1,3,4]. In humans, *Salmonella enterica* serovar Typhi causes typhoid fever, a disease characterized by multi-organ bacterial colonization with common immunopathological manifestations in the gastrointestinal tract and the hepatobiliary system [5].

The molecular and physiological bases of the metabolic disorders observed during infection are not fully understood. In this work, we examined the disruption of the enterohepatic fibroblast growth factor 15/19 (FGF15/19)-fibroblast growth factor receptor 4 (FGFR4) endocrine axis during bacterial infections of the enterohepatic system. FGF15/19 (FGF15 in mice, FGF19 in humans) is an endocrine factor secreted by intestinal enterocytes [6]. FGF15/19 has a crucial role in the control of whole body glucose and lipid metabolism and energy expenditure [7,8]. It is also a key regulator of de novo synthesis of bile acids via the repression of cholesterol 7 alpha hydroxylase (CYP7A1) expression in hepatocytes [9]. In addition, FGF15 represses the apical Na⁺-dependent bile acid transporter (ASBT) expression in hepatic cholangiocytes [10] and facilitates gallbladder filling by promoting gallbladder muscle distension [11]. Through these functions, FGF15/19 closes an important negative feedback loop in the regulation of bile acid homeostasis. Signaling to hepatic target cells occurs through the interaction of FGF15/19 with the tyrosine kinase receptor fibroblast growth factor receptor

* Correspondence: alfredo.menendez@usherbrooke.ca

¹Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, University of Sherbrooke, Cancer Research Pavilion, Rm Z8-1072, 3201, rue Jean-Mignault, Sherbrooke, Québec J1E 4K8, Canada
Full list of author information is available at the end of the article

4 (FGFR4) and also requires the protein β Klotho. Mice genetically deficient for *Fgf15*, *Fgfr4* or *Klb* (β Klotho) have similar biliary phenotypes with higher levels of CYP7A1 and increased synthesis of bile acids [6,12-14]. Reduced FGF19 levels have been observed in patients with inflammatory bowel disease [15] and chronic idiopathic bile acid diarrhea [16]. On the other hand, patients with insulin resistance and non-alcoholic fatty liver disease, as well as extrahepatic cholestasis frequently display elevated plasma levels of FGF19 [17,18].

Using a model of murine typhoid fever, we demonstrate that *Salmonella enterica* infection triggers major alterations in the hepatic biliary function gene expression program, promotes accumulation of hepatic cholesterol and triglycerides and leads to a significant reduction in physiological gallbladder bile volumes. In addition, *Salmonella* infection causes a substantial decrease in the expression of intestinal *Fgf15*, accompanied by a dramatic loss of hepatic FGFR4 and β Klotho. These disturbances appear to be secondary to hepatic inflammation. Given the important role of the FGF15/19-FGFR4 endocrine axis as a central metabolic regulator, these alterations may be a major factor underlying the pathophysiology of bacterial infectious diseases.

Methods

Bacterial strains and mouse infections

Salmonella enterica serovar Typhimurium strains SL1344 (Sm^r) and SB103 (*invA*) [19] and *Listeria monocytogenes* 10403 s (Sm^r) [20] were used in this study. Bacteria were grown overnight at 37°C in LB supplemented with 100 μ g/mL streptomycin. Inoculum was prepared in sterile HEPES 100 mM, NaCl 0.9%, pH 8.0. Animal protocols were approved by the Animal Care Committees of the University of British Columbia and the University of Sherbrooke. Eight weeks-old female C57BL/6 mice (The Jackson Laboratory, Bar Harbor, USA) were infected orally with 5×10^7 *Salmonella* SL1344, intravenously with 5×10^2 *Salmonella* SB103 or with *Listeria* 10403 s (2×10^9 bacteria orally and 10^4 intravenously). The animals were kept with food and water *ad libitum* through the duration of the study and were always sacrificed during the light period (10:00 AM \pm 60 minutes). The bile was collected by gallbladder resection and draining by puncture. For bacterial counts, tissues were homogenized using a Mixer Mill MM400 (Retsch GmbH) followed by plating of serial dilutions in LB plates containing 100 μ g/mL streptomycin. All infection experiments were done in duplicate using a total of 8–10 mice per group.

Expression analyses

Ileum and liver samples were collected for mRNA and protein analysis. The ileal samples were taken approximately 2 cm away from the ileo-cecal junction; liver

samples were taken from the central lobule. RNA was extracted using the RNeasy kit (Qiagen) and cDNA was prepared using the Quantitech Reverse Transcription kit (Qiagen). Quantitative PCR (qPCR) were done on an Eppendorf RealPlex² system using the DyNamo SYBR Green qPCR Kit (Thermo Scientific). All reactions were done in 10 μ l final volume with 40 cycles of 30 seconds denaturing at 95°C, 30 seconds annealing at 60°C and 30 seconds extension at 72°C (except the annealing temperature for Ost β : 62°C). The relative expressions were calculated using the ddCt method and corrected for primer efficiencies according to Pfaffl *et al.* [21]. The qPCR primers are listed in Table 1. Western blots were performed using total liver tissue lysates and antibodies against CYP7A1 (Abcam, ab65596, 1:1000), FGFR4 (Abcam, ab119378, 1:500), β Klotho (R&D, AF2619, 1:2000) and actin (SIGMA A4700, 1:1000).

Microscopy

For histological analysis, tissue sections were fixed in 10% buffered formalin, embedded in paraffin and stained with H&E. Alternatively, samples fixed in 3.5% paraformaldehyde and frozen-embedded in OCT were used for immunofluorescent microscopy as previously described [22]. Fluorescence was visualized using an Olympus IX81 microscope.

Cholesterol and triglyceride determinations

Cholesterol and triglycerides were assayed in liver lysates. A total of 40–100 mg of liver was homogenized with an ultra turrax (setting 5, 4 times for 15 sec) in 3 ml of chloroform:methanol (2:1), extracted twice with water, and centrifuged for 15 minutes at 3000g. For the triglyceride assay 200 μ l of the organic layer (lower phase) was removed and evaporated under N₂(g). 10 μ l of Thesit (Sigma-Aldrich, St Louis, MO) was added and mixed under N₂(g). Water (50 μ l) was added and incubated at 37°C for 1 hr with intermittent vortexing. Aliquots of 5 μ l were assayed using the Serum Triglyceride Determination kit (Sigma-Aldrich, St Louis, MO) modified for a 96-well plate, calibrated with a trioleate (Sigma-Aldrich, St Louis, MO) standard curve. The cholesterol assay was performed at the same time but 500 μ l of the organic layer (lower phase) was removed after the centrifugation step and evaporated under N₂(g). 50 μ l of isopropanol was then added to the dried down lipids and mixed by vortexing. Aliquots of 2 μ l were then assayed using the Cholesterol E kit (Wako Chemicals USA, Richmond, USA).

Statistical analyses

Data processing and statistical analyses were performed using GraphPad Prism5. Student's *t* test was applied to all sets of data for statistical comparisons between

Table 1 The genes analyzed in this study and the sequences of the qPCR primer sets

Gene	Official symbol	Product	Primers
Abcg5	<i>Abcg5</i>	ATP-binding cassette, sub-family G (WHITE), member 5	TGTCAACAGTATAGTGGCTCTG CGTAAAACCTATTGACCACGAG
Abcg8	<i>Abcg8</i>	ATP-binding cassette, sub-family G (WHITE), member 8	CTTGCTCCTCGCTATAGCAACC TTTCCACAGAAAGTCATCAAAGC
Asbt	<i>Slc10a2</i>	Apical sodium-dependent bile acid transporter	ACCTTCCCACTCATCTATACTG CAAATGATGGCCTGGAGTCC
Bsep	<i>Abcb11</i>	Bile salt export pump	CAACGCATTGCTATTGCTCGG TAGACAAGCGATGAGCAATGAC
Cyp7a1	<i>Cyp7a1</i>	Cholesterol 7 alpha hydroxylase	GGGAATGCCATTACTTGGATC TATAGGAACCATCCTCAAGGTG
Fabp6	<i>Fabp6</i>	Fatty acid binding protein 6	GAATTACGATGAGTTCATGAAGC TTGCCAATGGTGAACCTGTTGC
Fgf15	<i>Fgf15</i>	Fibroblast growth factor 15	AGACGATTGCCATCAAGGACG GTACTGGTTGTAGCCTAAACAG
Fgfr4	<i>Fgfr4</i>	Fibroblast growth factor receptor 4	CTCGATCCGCTTTGGGAATTC CAGGTCTGCCAAATCCTTGTC
FXR	<i>Nr1h4</i>	Farnesoid X receptor (nuclear receptor subfamily 1, group H, member 4)	GTTCCGGCGAGATTTTCAATAAG AGTCATTTTGAGTTCTCCAACAC
β Klotho	<i>Klb</i>	Beta Klotho	AACAGCTGTCTACTGTGGG ATGGAGTGCTGGCAGTTGATC
Mdr1a	<i>Abcb1a</i>	ATP-binding cassette, sub-family B member 1a	CCGATAAAGAGCCATGTTTGC CTTCTGCCTGATCTTGTGTATC
Mdr1b	<i>Abcb1b</i>	ATP-binding cassette sub-family B member 1b	GGACCCAACAGTACTCTGATC ACTTCTGCCTAATCTTGTGTATC
Mdr2	<i>Abcb4</i>	Multidrug resistance protein 2	TTGTCAATGCTAAATCCAGGAAG AGTTCAGTGGTGCCCTTGATG
Mrp2	<i>Abcc2</i>	ATP-binding cassette, sub-family C (CFTR/MRP) member 2	GGCTCATCTCAAATCCTTTGTG TTTTGGATTTTCGAAGCACGGC
Mrp3	<i>Abcc3</i>	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	GAACACGTTTCGTGAGCAGCC ATCCGTCTCCAAGTCAATGGC
Mrp4	<i>Abcc4</i>	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	TACAAGATGGTTCAGCAACTGG GTCCATTGGAGGTGTTTCATAAC
Ntcp	<i>Slc10a1</i>	Sodium-taurocholate co-transporting polypeptide	CGTCATGACACCACCTTACTG GATGGTAGAACAGATTGGACG
Osta	<i>Osta</i>	Organic solute transporter alpha	TCTCCATCTTGGCTAACAGTG GATAGTACATTCGTGTCAGCAC
Ostb	<i>Ostb</i>	Organic solute transporter beta	CCACAGTGCAGAGAAAGCTGC ACATGCTTGTGATGACCACCAG
Shp	<i>Nr0b2</i>	Small heterodimer partner	AGTCTTTCTGGAGCCTTGAGC TTGCAGGTGTGCGATGTGGC

Table 1 The genes analyzed in this study and the sequences of the qPCR primer sets (Continued)

Srbl	<i>Scarb1</i>	Scavenger receptor class B type 1	GAACTGTTCTGTGAAGATGCAG GCGTGATAGAACGTGCTCAGG
36B4	<i>Rplp0</i>	Ribosomal protein, large, P0	TCTGGAGGGTGTCCGCAAC CTTGACCTTTTCAGTAAGTGG

The top sequence of each set corresponds to the forward primer and the bottom one to the reverse. All reactions were done in 10 µl final volume with 40 cycles of 30 seconds denaturing at 95°C, 30 seconds annealing at 60°C and 30 seconds extension at 72°C (except annealing temperature for Ostβ, which was 62°C).

groups, the graphs show the means and the standard errors of the mean.

Results

Enterohepatic infections downregulate the expression of intestinal *Fgf15*

The terminal ileum is the main site of production of FGF15, it is also a major port of entry for *Salmonella* and therefore, an important site for its pathogenesis. To determine the effect of *Salmonella* infection on the homeostatic synthesis of FGF15, we collected tissue samples from infected animals and analyzed the abundance of *Fgf15* transcripts by qPCR. As shown in Figures 1A and 1B, the level of *Fgf15* transcripts inversely correlated with bacterial counts in the liver and the ileum, with a statistically significant decrease observed at mid-high infection

levels. While H&E-stained sections from the ileum of infected animals did not show signs of pathological alteration (Figure 1C), staining of liver sections demonstrated a strong inflammatory response evidenced by large lesions with widespread lymphocytic infiltration, extensive necrosis often accompanied by local hemorrhage, and zones of parenchymal degeneration characterized by disappearance of hepatocytes (Figure 1D).

FGF15 is synthesized by enterocytes [6], which can also be invaded by *Salmonella* [23]. However, the decrease in *Fgf15* expression was not associated with damage to the ileal enterocyte layer (Figure 1C). This suggests that loss of ileal enterocytes is not the reason for reduced *Fgf15* transcript levels. Oral infections with *Listeria monocytogenes*, an inefficient invader of the mouse intestinal epithelium [24,25], showed no significant liver colonization and




Figure 1 Oral infection with *Salmonella typhimurium* SL1344 decreases the expression of *Fgf15* in the ileum. (A) bacterial counts in infected ilea and livers; animals were arbitrarily grouped into low, medium and high infection levels (10^0 - 10^3 , 10^4 - 10^5 and $>10^6$ cfu/mg, respectively roughly corresponding to 72, 96 and 120 hours post-infection; UI: uninfected). (B) relative levels of *Fgf15* transcripts in the ilea of infected mice (data by qPCR). (C) H&E staining of ileum sections from representative uninfected and orally *Salmonella*-infected animals (ileal colonization of the infected animal = 2.2×10^5 cfu/mg); scale bars are 200 µm. (D) H&E staining of liver sections from representative uninfected and orally *Salmonella*-infected animals (liver colonization of the infected animal = 1.7×10^5 cfu/mg); scale bars are 800 and 400 µm.

large numbers of intestinal bacteria but not downregulation of *Fgf15* expression (Figure 2A). In contrast, intravenous infections with *Listeria*, which colonized the liver rapidly and triggered decreases in the transcript levels of biliary function genes (Figure 2B), caused a significant reduction in ileal *Fgf15* expression (Figure 2A). These results point to hepatic pathophysiology, rather than intestinal bacterial colonization, as the primary event driving downregulation of intestinal *Fgf15* expression.

To establish the role of hepatic colonization and to probe the involvement of bacterial enterocyte invasion in repressing *Fgf15* expression, we carried out intravenous infections with the *Salmonella* invasion-deficient strain SB103 following Menendez et al. [22]. In this type of infection, *Salmonella* colonization of the hepatobiliary system occurs immediately whereas colonization of the gut is delayed by 72 to 96 hours [22]. Furthermore, the bacteria that eventually reach the intestines are unable to invade the enterocytes due to the *invA* mutation of this strain. As shown in Figure 2C, intravenous infection with *Salmonella* SB103 caused a reduction of *Fgf15* transcripts abundance. Notably, such a decrease was observed

with a much lower intestinal bacterial burden than those in oral infections with the wild-type strain (average 10^2 vs. 10^7 cfu/mg, respectively). These results demonstrate that colonization of the hepatobiliary system by *Salmonella* represses the expression of intestinal *Fgf15* and show that enterocyte invasion by intestinal bacteria does not play a major role on this effect.

Transcription of *Fgf15* in ileal enterocytes is transactivated by the nuclear receptor FXR (Farnesoid X Receptor), upon its activation by bile acids [7]. Expression of the FXR gene (*Nr1h4*) was not affected by *Salmonella*, regardless of the intestinal bacterial burden (data not shown). In contrast, the expression of other known intestinal FXR target genes, *Fabp6* (Fatty acid binding protein 6), *Nr0b2* (Small heterodimer partner, Shp) [26] and *Osta* (Organic solute transporter alpha) [27], was decreased by *Salmonella* infection in a pattern similar to that of *Fgf15* with maximal, significant drops in highly-infected animals (Figure 3A). This suggests that activation of gene expression mediated by FXR is impaired during infection.

Colonization of the hepatobiliary system by *Salmonella* induces local pathological damage and inflammation [22],




Figure 2 Liver colonization drives the downregulation of ileal *Fgf15* expression. (A) relative levels of *Fgf15* transcripts in the ileum of mice infected orally or intravenously with *Listeria monocytogenes*. (B) transcript levels of genes involved in liver biliary metabolism in mice infected intravenously with *Listeria monocytogenes*, relative to the levels of uninfected animals (defined as 1, dashed line). (C) relative levels of *Fgf15* transcripts in the ilea of mice infected intravenously with *Salmonella typhimurium* SB103 (*invA*), at 120 hours post-infection. Data by qPCR, *p < 0.05.




Figure 3 Infection with *Salmonella* decreases the expression of FXR-target genes in the ileum. **(A)** Relative levels of *Fabp6*, *Nr0b2* and *Osta* transcripts in the ileum of mice orally infected with *Salmonella typhimurium* SL1344. Animals were arbitrarily grouped into low, medium and high infection levels (10^2 - 10^3 , 10^4 - 10^5 and $>10^6$ cfu/mg, respectively roughly corresponding to 72, 96 and 120 hours post-infection; UI: uninfected). **(B)** *Fgf15* transcript levels in the ilea of uninfected mice fed 5% cholestyramine diet. Data by qPCR, **p < 0.01; ***p < 0.001; ****p < 0.0001.

which can result in impaired synthesis of bile acids and inflammation-induced cholestasis [28]. This may in turn, compromise intestinal FXR activation and lead to inhibition of *Fgf15*, *Fabp6*, *Nr0b2* and *Osta* expression. To test whether the depletion of bile acids would be sufficient to decrease *Fgf15* expression *in vivo*, we fed uninfected C57BL/6 mice with a diet supplemented with the bile acid sequestrant cholestyramine. As shown in Figure 3B mice fed with cholestyramine did have significantly lower levels of *Fgf15* transcripts than mice fed with a normal diet.

Second, we evaluated the effects of *Salmonella* infection in bile production and flow. Gallbladder bile volumes were measured before and during infection; a significant reduction in volume was observed 24 hours post-infection, which did not improved over the next 4 days (Figure 4A). An expression analysis of hepatic genes involved in bile

synthesis and secretion (Figure 4B), showed striking reductions in the transcript levels of the major transporters of bile acid and cholesterol (*Abcb11*, *Slc10a1*, *Abcb1a*, *Abcg5* and *Abcg8*) and the induction of several genes involved in rescue from cholestasis. The mRNA (Figure 5A) and protein levels (Figure 5B) of CYP7A1, the rate-limiting enzyme in the neutral pathway of bile acids synthesis, were decreased by infection. This was accompanied by a significant accumulation of hepatic cholesterol and triglycerides (Figure 5C and Figure 5D), which collectively suggest interruption of bile synthesis and flow.

Salmonella infection leads to depletion of the hepatic FGF15 receptor complex

Signaling of FGF15 in hepatocytes requires the tyrosine kinase membrane receptor FGFR4 and the protein




Figure 4 *Salmonella* infection perturbs the host's hepatobiliary homeostasis. **(A)** bile volumes recovered from the gallbladders of mice orally infected with *Salmonella* at the indicated hours post-infection (hpi). **(B)** Transcript levels of hepatic genes involved in liver biliary metabolism in mice infected with *Salmonella*, relative to the levels of uninfected animals (defined as 1, dashed line) at 24, 72 and 120 hours post-infection. Data by qPCR.




Figure 5 *Salmonella* infection downregulates the neutral bile acid synthesis pathway. (A) relative levels of liver *Cyp7a1* transcripts in mice infected with *Salmonella*. (B) CYP7A1 western blot of liver lysates. (C) Cholesterol and (D) triglycerides accumulation in the liver of *Salmonella*-infected vs. uninfected mice, (* $p < 0.05$; **** $p < 0.0001$).


β Klotho. To determine if *Salmonella* infection disturbs the homeostasis of this pathway, we analyzed the levels of FGFR4 and β Klotho in infected and uninfected livers. Figures 6A and 6B show that the transcript levels of both *Fgf4* and *Klb* (β Klotho) were significantly decreased by infection. In addition, the protein levels were also reduced, as evidenced by western blot (Figure 6C). Two major FGFR4 bands were detected in uninfected animals, with apparent molecular weights of 115 and 125 KDa, likely corresponding to the core-glycosylated (FGFR4₁₁₅) and fully-glycosylated, functional (FGFR4₁₂₅) forms of FGFR4, respectively [29]. Infection led to the disappearance of FGFR4₁₂₅ and a decrease of FGFR4₁₁₅. Immunofluorescent staining of liver sections confirmed the reduction of FGFR4 and β Klotho. Both proteins were clearly detected in uninfected hepatocytes (Figure 6D); in contrast, hepatocytes from *Salmonella*-infected livers were devoid of FGFR4 and β Klotho.

Discussion

The FGF19-FGFR4 endocrine axis is currently considered a potential intervention point for the therapy of cancer, gallstone disease, and metabolic disorders associated to the metabolic syndrome [7,30]. Experimental administrations of FGF19 and transgenic FGF19 mice have shown decreased liver fat content, improved hepatic and serum lipid profiles, and resistance to high-fat

diet-induced obesity [31-33]. In addition, FGF15/19 induces hepatocyte proliferation [34] and has been recently identified as an important mediator of liver regeneration after liver resection surgery [35]. Here we show that *Salmonella* infection disturbs the homeostasis of the FGF15/19-FGFR4 axis by down-regulating the expression of *Fgf15*, *Fgf4* and *Klb*. To our knowledge, these results constitute the first demonstration of a pathophysiological effect of bacterial infections over the FGF15/19-FGFR4 endocrine axis.

Infection modified both the ileal expression of *Fgf15* and the components of its hepatic receptor, which suggests a significant functional shutdown of the pathway. Our data rules out a direct cytopathic effect of bacteria over ileal enterocytes as the major cause of *Fgf15* mRNA reductions. Instead, it is apparent that the decline in *Fgf15* expression results from impaired activation of FXR in the enterocytes. Our interpretation is strongly supported by the observed low volumes of gallbladder bile and the decreased expression of *Fabp6*, *Osta* and *Nr0b2* (Shp), all well-known FXR targets. In addition, we show that the depletion of the intestinal bile acids pool by oral administration of the bile acid sequestrant cholestyramine is sufficient to significantly decrease ileal *Fgf15* expression. Furthermore, intravenous infections with a *Salmonella* invasion mutant and with *Listeria monocytogenes*, both resulting in rapid hepatic colonization and pathophysiology, lead to reductions in



Fgf15 expression in the absence of significant ileal bacterial colonization or enterocyte invasion.

Salmonella infection induced a massive alteration of the hepatobiliary gene expression program. Remarkably, the mRNA and protein levels of CYP7A1, the rate-limiting enzyme in the neutral pathway of bile acids synthesis were decreased during infection, in spite of the lower levels of FGF15 which would be expected to promote the upregulation of *Cyp7a1* expression. These results reveal the complexities in the regulation of *Cyp7a1* expression and indicates that the mechanisms of *Cyp7a1* expression control are hierarchical. Infection also triggered a significant reduction of FGFR4 and β Klotho, the two proteins involved in assembling the functional receptor for FGF15 in hepatocytes. The biology of FGFR4 and β Klotho had never before been studied in the context of a bacterial insult, and our data suggest that their function can be severely compromised by bacterial infections *in vivo*. The mechanisms underlying their downregulation are unclear at present but we anticipate that they are related to the pro-inflammatory cytokine burst that follows liver colonization by bacteria. It has been recently reported that TNF α

represses β Klotho expression in adipocytes [36]; thus it is possible that a similar mechanism acts in hepatocytes.

It is apparent that the dysregulation of the FGF15/19-FGFR4 endocrine axis components is not a general pathogenic feature of all bacteria, as infections with the enteric pathogen *Citrobacter rodentium*, the mouse model for human EPEC and EHEC [37], did not modify the expression of ileal *Fgf15* (data not shown). Instead, this pathophysiological effect may be restricted to infections displaying a relevant liver involvement. Further work is still necessary to define the full impact of infections in FGF15/19 function and to determine the underlying molecular mechanisms.

Conclusions

Through the alteration of the hepatobiliary function, bacterial pathogens of the enterohepatic system dysregulate the homeostasis of the FGF15/19-FGFR4 endocrine axis. These revealing findings have important implications for the understanding of the pathophysiology of microbial diseases. Disruption of the FGF15/19-FGFR4 pathway may be a contributing factor to the metabolic

and nutritional disorders associated with infectious diseases.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GR, ST, ETA and LCMA carried out *Salmonella* infections. GR performed the gene expression analysis, western blots and immunofluorescent microscopy. SC and ETA performed the cholesterol and triglyceride determinations. MTC carried out the *Listeria* infections. BBF participated in the supervision of the study. GR and AM drafted the manuscript. AM conceived the study and supervised its design, coordination and execution. All authors read and approved the final manuscript.

Acknowledgments

We thank Catherine Desrosiers, Melisange Roux and Elora Midavaine for technical help. This work was supported by grants to A.M. from the Fonds de Recherche du Québec-Santé (26710) and the Natural Sciences and Engineering Research Council of Canada (401949–2011), and to B.B.F. from the Canadian Institutes for Health Research. L. C. M. A. was funded by a postdoctoral fellowship from the Canadian Institutes of Health Research. A. M. is a member of the FRQS-funded Centre de Recherche Clinique Étienne-Le Bel.

Author details

¹Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, University of Sherbrooke, Cancer Research Pavilion, Rm Z8-1072, 3201, rue Jean-Mignault, Sherbrooke, Québec J1E 4K8, Canada.

²Michael Smith Laboratories, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada. ³Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

⁴Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. ⁵Present address: Unité de Pathogénie Microbienne Moléculaire Institut Pasteur, 28 rue du Dr Roux, F – 75724, Paris Cédex 15, France. ⁶Present address: Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rua Leopoldo Bulhões, 1480, Rio de Janeiro, RJ 21041-210, Brazil. ⁷Present address: Qu Biologics Inc, 887 Great Northern Way, Suite 138, Vancouver, BC V5T 4T5, Canada.

Received: 18 June 2013 Accepted: 26 October 2013

Published: 29 October 2013

References

1. Powanda MC, Beisel WR: **Metabolic effects of infection on protein and energy status.** *J Nutr* 2003, **133**(1):322S–327S.
2. McGuinness OP: **Defective glucose homeostasis during infection.** *Annu Rev Nutr* 2005, **25**:9–35.
3. Khosla SN: *Typhoid fever. Its cause, transmission and prevention.* New Delhi: Atlantic Publishers; 2008.
4. Antunes LC, Arena ET, Menendez A, Han J, Ferreira RB, Buckner MM, Lolic P, Madilao LL, Bohlmann J, Borchers CH, et al: **Impact of salmonella infection on host hormone metabolism revealed by metabolomics.** *Infect Immun* 2011, **79**(4):1759–1769.
5. Parry CM: **Epidemiological and clinical aspects of human typhoid fever.** In *Salmonella infections: clinical, immunological and molecular aspects.* Edited by Mastroeni P, Maskell D. Cambridge, New York: Cambridge University Press; 2006.
6. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, et al: **Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.** *Cell Metab* 2005, **2**(4):217–225.
7. Jones SA: **Physiology of FGF15/19.** In *Endocrine FGFs and Klothos.* Edited by Kuro-o M. New York: Landes Bioscience and Springer Science; 2012:171–182.
8. Potthoff MJ, Kliever SA, Mangelsdorf DJ: **Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.** *Genes Dev* 2012, **26**(4):312–324.
9. Chiang JY: **Bile acids: regulation of synthesis.** *J Lipid Res* 2009, **50**(10):1955–1966.
10. Sinha J, Chen F, Miloh T, Burns RC, Yu Z, Shneider BL: **Beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes.** *Am J Physiol Gastrointest Liver Physiol* 2008, **295**(5):G996–G1003.
11. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, Suino-Powell K, Xu HE, Richardson JA, Gerard RD, et al: **Identification of a hormonal basis for gallbladder filling.** *Nat Med* 2006, **12**(11):1253–1255.
12. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL: **Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4.** *J Biol Chem* 2000, **275**(20):15482–15489.
13. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y: **Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho.** *J Clin Invest* 2005, **115**(8):2202–2208.
14. Kuro-o M: **Klotho and betaKlotho.** *Adv Exp Med Biol* 2012, **728**:25–40.
15. Lenicek M, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z, Vitek L: **Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers.** *Inflamm Bowel Dis* 2011, **17**(6):1322–1327.
16. Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW: **A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.** *Clin Gastroenterol Hepatol* 2009, **7**(11):1189–1194.
17. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL: **High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.** *Hepatology* 2009, **49**(4):1228–1235.
18. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG: **The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.** *Am J Physiol Gastrointest Liver Physiol* 2010, **298**(3):G440–G445.
19. Galan JE, Curtiss R 3rd: **Distribution of the invA, -B, -C, and -D genes of Salmonella typhimurium among other Salmonella serovars: invA mutants of Salmonella typhi are deficient for entry into mammalian cells.** *Infect Immun* 1991, **59**(9):2901–2908.
20. Bishop DK, Hinrichs DJ: **Adoptive transfer of immunity to Listeria monocytogenes. The influence of in vitro stimulation on lymphocyte subset requirements.** *J Immunol* 1987, **139**(6):2005–2009.
21. Pfaffl MW: **A new mathematical model for relative quantification in real-time RT-PCR.** *Nucleic Acids Res* 2001, **29**(9):e45.
22. Menendez A, Arena ET, Guttman JA, Thorson L, Vallance BA, Vogl W, Finlay BB: **Salmonella infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute typhoid fever.** *J Infect Dis* 2009, **200**(11):1703–1713.
23. van Asten AJ, Koninkx JF, van Dijk JE: **Salmonella entry: M cells versus absorptive enterocytes.** *Vet Microbiol* 2005, **108**(1–2):149–152.
24. Okamoto M, Nakane A, Minagawa T: **Host resistance to an intragastric infection with Listeria monocytogenes in mice depends on cellular immunity and intestinal bacterial flora.** *Infection and immunity* 1994, **62**(8):3080–3085.
25. Lecuit M: **Understanding how Listeria monocytogenes targets and crosses host barriers.** *Clin Microbiol Infect* 2005, **11**(6):430–436.
26. De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ, Dufour JF: **The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer.** *Dig Dis Sci* 2004, **49**(6):982–989.
27. Frankenberg T, Rao A, Chen F, Hayward J, Shneider BL, Dawson PA: **Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids.** *Am J Physiol Gastrointest Liver Physiol* 2006, **290**(5):G912–G922.
28. Kusters A, Karpen SJ: **The role of inflammation in cholestasis: clinical and basic aspects.** *Semin Liver Dis* 2010, **30**(2):186–194.
29. Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL: **Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.** *Hepatology* 2010, **52**(2):656–666.
30. Wu X, Li Y: **Therapeutic utilities of fibroblast growth factor 19.** *Expert Opin Ther Targets* 2011, **15**(11):1307–1316.
31. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, et al: **Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.** *Endocrinology* 2002, **143**(5):1741–1747.
32. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, et al: **Fibroblast growth factor 19 increases**

- metabolic rate and reverses dietary and leptin-deficient diabetes. *Endocrinology* 2004, **145**(6):2594–2603.
33. Bhatnagar S, Damron HA, Hillgartner FB: **Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis.** *J Biol Chem* 2009, **284**(15):10023–10033.
 34. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, *et al*: **FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.** *J Biol Chem* 2010, **285**(8):5165–5170.
 35. Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion AR, *et al*: **Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice.** *Gut* 2013, **62**(6):899–910.
 36. Diaz-Delfin J, Hondares E, Iglesias R, Giral M, Caelles C, Villarroya F: **TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway.** *Endocrinology* 2012, **153**(9):4238–4245.
 37. Diez E, Zhu L, Teatero SA, Paquet M, Roy MF, Loredano-Osti JC, Malo D, Gruenheid S: **Identification and characterization of Cri1, a locus controlling mortality during *Citrobacter rodentium* infection in mice.** *Genes Immun* 2011, **12**:280–290.

doi:10.1186/1471-2180-13-238

Cite this article as: Romain *et al.*: Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis. *BMC Microbiology* 2013 **13**:238.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

